Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

39

Revenue 2017

Orencia

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Orencia was produced by Bristol-Myers Squibb.

BMS plans major expansion of Orencia plant

BMS plans major expansion of Orencia plant Devens manufactures bulk biologic drugs and is the main site for the production of BMS' fast-growing rheumatoid arthritis treatment Orencia (abatacept), and currently employs around 400 workers.

NICE metrics flawed and should not be used, says EU study

NICE metrics flawed and should not be used, says EU study The researchers cited the negative NICE appraisals of Bristol Myers Squibb's Orencia (abatacept) for rheumatoid arthritis (RA) as evidence of the flawed approach. ... Since then BMS has reduced the price of Orencia and draft guidance now backs its use in

BMS Q4 results see earnings increase despite fall in sales

BMS Q4 results see earnings increase despite fall in sales Among these, rheumatoid arthritis drug Orencia (abatacept) grew 26 per cent to $325m, while Yervoy (ipilimumab) for melanoma raced ahead 47 per cent to bring in $211m in the quarter and

BMS/Ono enter extended agreement

The other agreement created is for the co-development and co-commercialisation of Orencia (abatacept) in Japan. ... Bristol-Myers K.K. (BMS's Japanese subsidiary) will distribute and book sales of Orencia IV.

Orencia

Orencia campaign. Created by Sudler & Hennessey for Bristol-Myers Squibb. Therapy area: Musculo-skeletal Disorders

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...